BioSight
Companies
ARS Pharmaceuticals, Inc. logo

SPRY

NASDAQSAN DIEGO, CA
ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals develops intranasal epinephrine products for treating allergic reactions, with their lead product neffy already approved and marketed. The company is working to expand neffy's geographic availability through regulatory filings and partnerships, while also researching additional intranasal epinephrine candidates for future development.

Price history not yet available for SPRY.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar